NCT07425938

Brief Summary

The main goal of this study is to investigate the modulatory effects of intranasally administrated oxytocin on the processing of emotional stimuli and its acting routes.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 24, 2026

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

January 28, 2026

Completed
26 days until next milestone

First Posted

Study publicly available on registry

February 23, 2026

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2026

Completed
Last Updated

February 23, 2026

Status Verified

February 1, 2026

Enrollment Period

3 months

First QC Date

January 28, 2026

Last Update Submit

February 20, 2026

Conditions

Healthy Adult Male

Keywords

oxytocinnegative emotionvasoconstrictor

Outcome Measures

Primary Outcomes (2)

  • Brain activity in response to emotional stimuli during task-based fMRI scanning

    Subjects receive task fMRI scanning after treatment. The investigators will compare the activation differences in the brain, specifically focusing on the amygdala, among three groups.

    1 hour

  • Changes in plasma oxytocin concentrations

    Blood samples will be collected two times, with one sample collected after finishing questionnaires and the other one 30-minute post-treatment.

    After finishing questionnaires and 30-minute post-treatment

Secondary Outcomes (4)

  • The valence rating in response to different emotional stimuli

    40 minutes

  • The intensity rating in response to different emotional stimuli

    40 minutes

  • The arousal rating in response to different emotional stimuli

    40 minutes

  • Resting-state fMRI

    17 minutes in total with each lasting around 8.5 minutes.

Study Arms (3)

Placebo and oxytocin group

EXPERIMENTAL

Subjects receive placebo of vasoconstrictor and oxytocin treatment

Drug: placebo (compared to vasoconstrictor)Drug: oxytocin

Vasoconstrictor and oxytocin group

EXPERIMENTAL

Subjects receive vasoconstrictor and oxytocin treatment

Drug: vasoconstrictor (Otrivin)Drug: oxytocin

Vasoconstrictor and placebo group

PLACEBO COMPARATOR

Subjects receive vasoconstrictor and placebo of oxytocin treatment

Drug: vasoconstrictor (Otrivin)Drug: placebo (compared to oxytocin)

Interventions

placebo (compared to vasoconstrictor)DRUG

intranasal administration of placebo (4 sprays of 0.9% saline and glycerin)

Placebo and oxytocin group
vasoconstrictor (Otrivin)DRUG

intranasal administration of vasoconstrictor (4 sprays of 0.9% Otrivin)

Vasoconstrictor and oxytocin groupVasoconstrictor and placebo group
placebo (compared to oxytocin)DRUG

intranasal administration of placebo (24 IU)

Vasoconstrictor and placebo group
oxytocinDRUG

intranasal administration of oxytocin (24IU)

Placebo and oxytocin groupVasoconstrictor and oxytocin group

Eligibility Criteria

Age18 Years - 30 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsIndividuals whose self-identified gender is consistent with their biological sex.
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy subjects without past or current psychiatric or neurological disorders

You may not qualify if:

  • History of head injury.
  • Medical or psychiatric illness.
  • Subjects take a certain drug for a long period of time.
  • Subjects have metal implants in their bodies.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Electronic Science and Technology of China (UESTC)

Chengdu, Sichuan, 611731, China

RECRUITING

MeSH Terms

Interventions

Vasoconstrictor AgentsxylometazolineOxytocin

Intervention Hierarchy (Ancestors)

Cardiovascular AgentsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesPituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Shuxia Yao, Dr

    University of Electronic Science and Technology of China

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Shuxia Yao, Dr

CONTACT

+86 18111297596yaoshuxia@uestc.edu.cn

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 28, 2026

First Posted

February 23, 2026

Study Start

January 24, 2026

Primary Completion

April 15, 2026

Study Completion

April 15, 2026

Last Updated

February 23, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)